Serum Neurofilament Light Chain as a Biomarker for Cognitive Impairment in Parkinson's Disease
Author Information
Author(s): Gu Lihua, Zhang Pengcheng, Gao Rui, Shu Hao, Wang Pan
Primary Institution: Tianjin Huanhu Hospital, Tianjin, China
Hypothesis
The levels of blood-derived neurofilament light chain (NfL) and its accumulation during Parkinson's disease progression could serve as a potential biomarker for predicting subsequent cognitive decline.
Conclusion
Serum NfL levels increase as Parkinson's disease progresses and can predict cognitive impairment within a 2-year timeframe.
Supporting Evidence
- Serum NfL levels were significantly higher in PD-CN patients compared to NC.
- PD patients with high serum NfL levels were found to have a higher likelihood of transitioning from normal cognition to mild cognitive impairment or dementia.
- The area under the curve for PD-CN conversion to MCI or dementia was determined to be 0.684.
Takeaway
This study found that a protein in the blood called neurofilament light chain can help doctors see if someone with Parkinson's disease might have trouble thinking in the future.
Methodology
The study included 193 participants, with serum NfL concentrations measured and PD patients followed up for clinical assessment at an average of 2 ± 0.6 years.
Potential Biases
The study was conducted at a single center, which may limit the generalizability of the findings.
Limitations
The study may not apply to earlier stages of Parkinson's disease, and the predictive performance of serum NfL alone was modest.
Participant Demographics
Participants included 106 cognitively normal PD patients and 87 normal controls, aged between 40 and 85 years old, of Chinese Han ethnicity.
Statistical Information
P-Value
0.030
Confidence Interval
95% CI 1.010–1.213
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website